Compare BGSF & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | KZIA |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 74.1M |
| IPO Year | 2013 | 2002 |
| Metric | BGSF | KZIA |
|---|---|---|
| Price | $6.00 | $8.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.00 | ★ $17.67 |
| AVG Volume (30 Days) | 21.5K | ★ 194.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 33.33% | N/A |
| EPS Growth | ★ 67.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $272,499,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $0.64 |
| 52 Week High | $8.20 | $17.40 |
| Indicator | BGSF | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 64.10 |
| Support Level | $6.01 | $5.64 |
| Resistance Level | $6.38 | $8.94 |
| Average True Range (ATR) | 0.25 | 0.78 |
| MACD | -0.02 | 0.41 |
| Stochastic Oscillator | 59.35 | 85.66 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.